NCT01037231 - Phase 2/3 Oxabact Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions

Primary Hyperoxaluria

Interventions

BIOLOGICAL

Oxalobacter formigenes

NLT (not less than) 10\^7 CFU oxalobacter formigenes twice daily for 24 weeks

DRUG

Placebo

placebo

Trial Locations (3)

Mayo Clinic (Department of Pediatric Nephrology), Rochester

University Children's Hospital (Division of Pediatric Nephrology), Cologne

Academy Medical Center, University of Amsterdam, Amsterdam